From the category archives:

Stocks

Your President Is Lying About a “Strong Dollar Policy” – Why Dollar Weakness Matters

I couldn’t help but notice today that Pfizer started the trend we’ll see from every multinational today blaming lower 2012 forecasts on a stronger dollar (CNBC).  Pfizer has lowered their revenue projections by a full $200 Million.  Two Hundred Million Dollars!  … due to a stronger dollar.  And that’s just one company.  A strengthening dollar [...]

Read the full article →

Beware: Investing Newsletters Tend to Be Scammy, Lying, Useless Money Pits

Let’s imagine the easiest way to make a bunch of money for providing virtually no actual value, having very little accountability, and having the capability to scale your scam as much as you could ever imagine.  Here are a few common “business ventures” that come to mind: a) Virtually any of the top selling affiliate [...]

Read the full article →

If Stock Trading is Addictive, Options are CRACK

Is it possible to be a stock market addict?  Well, if you are a believer in the numerous other addictions in the American lexicon of late, ranging from sex addiction to internet addiction, then, you’d be hardpressed to say the euphoria and withdrawal associated with stock trading isn’t an addiction for many.  Like drugs and [...]

Read the full article →

9% Risk-Free Return in 1 Month: See How I Did It

It’s very rare that you hear the phrase “risk-free return” these days without it being tied to an FDIC-insured CD yielding south of 3%.  Heck, even US Treasuries are no longer considered risk-free by S&P following the recent credit downgrade and there are only 4 AAA companies left in the S&P500.  So, you’re probably thinking [...]

Read the full article →

Review: Chaikin Power Gauge Stock Rating Widget

As an occasional investors/trader, I like various tools, sources of information and a second opinion now and then before executing.  So, this week, I’m reviewing the Chaikin Power Gauge Stock Rating Widget you can see below.  Simply enter a stock symbol in that you’re interested in (everyone’s talking about Apple AAPL today).  To try it, [...]

Read the full article →

AAA Companies in the S&P500 – Only 4 Left!

AAA companies in the S&P500 index are now numbered at just 4 following the rating downgrade of Berkshire Hathaway earlier in the year.  Amazingly, these companies and dozens of sovereigns are now rated higher than US Treasury Bonds following Fitch’s downgrade of US debt: The US Has Lost its AAA Credit Rating – Here’s What [...]

Read the full article →

You Should NOT Be Losing Sleep Over This Market Crash

Markets are in turmoil and may well be for the foreseeable future.  Over the past few weeks, we’ve had the confluence of a burgeoning debt crisis in the Euro region with the impending debt ceiling deadline looming.  The deal the President and Congress agreed to was not digested well by global markets or by one [...]

Read the full article →

ImmunoCellular Therapeutics (IMUC) Review

Today we’re going to take a look at an interesting prospect in the early stage Biotech world – ImmunoCellular Therapeutics (IMUC). Company Profile ImmunoCellular Therapeutics an oncology firm based in California whose lead candidate ICT-107 is entering Phase II for patients with glioblastoma multiforme (GBM) which is a specific type of brain cancer.  IMUC’s lead [...]

Read the full article →

Portfolio Update – I Tripled the S&P500 – Again!

Wow, it’s been a long time since I’ve shared a portfolio update.  Since last update was in October (all portfolio updates here), it’s only fair to compare the performance of my holdings at that time from October to present versus the S&P500. So, if you held the same shares I did since last update (and [...]

Read the full article →

CytRx Corporation Stock Review

Today we’re going to take a look at an interesting prospect in the early stage Biotech world – CytRx Corporation (ticker: CYTR).  CytRx is focused on oncology drugs and has three primary drug candidates in the mid-late stage pipeline phases with prospects for various indications. Pipeline Review Here’s a recent snapshot of the pipeline indicating [...]

Read the full article →

← Previous Entries